New drug combo aims to outperform keytruda in head and neck cancer
NCT ID NCT07264075
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial is testing two new drug combinations—ivonescimab alone or with ligufalimab—against the standard treatment pembrolizumab (Keytruda) for people with advanced head and neck cancer that has come back or spread. The study will enroll about 780 participants to see if the new treatments help them live longer. The goal is to find a better first-line option for this type of cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (with or without ligufalimab) compared to pembrolizumab
What this could lead to
If successful, this could offer a new first-line treatment option for recurrent or metastatic head and neck cancer, potentially improving survival.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The experimental drugs may not outperform pembrolizumab, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA HEAD AND NECK CANCER (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Guillaume Le Conquerant
RECRUITINGLe Havre, 76600, France
Contact Phone: •••-•••-•••• Email: •••••@•••••